The strong EPS beat and margin expansion signal continued operational excellence. Monitor the conference call for 2026 guidance update and any commentary on end-market demand trends. The stock may see upward pressure from the EPS beat and margin story, but the revenue miss relative to consensus could create some near-term volatility.
Price Chart
Executive Summary
Thermo Fisher Scientific reported Q3 2026 revenue of $12.14B (+9% YoY) and adjusted EPS of $6.68 (+15% YoY), beating consensus estimates of $6.40 EPS and $12.86B revenue. Revenue growth was driven by 6% organic growth and strong performance across all segments, with GAAP operating margin expanding 120bps to 18.6%. The company did not provide updated guidance in the press release, stating it will be discussed on the conference call.
Key Financial Metrics
Key Facts
- Q3 2026 revenue grew 9% YoY to $12.14B, with 6% organic growth
- Adjusted EPS grew 15% YoY to $6.68, beating consensus of $6.40 (+4.4%)
- GAAP diluted EPS grew 9% to $4.64
- GAAP operating margin expanded 120bps to 18.6%; adjusted operating margin expanded 120bps to 24.5%
- All four business segments grew revenue and expanded margins YoY
- Free cash flow was $2.115B in Q3, up 15% YoY
- Completed divestiture of microbiology business during the quarter
- No updated 2026 guidance provided in the press release
Financial Impact
Revenue beat consensus by $12.14B vs $12.86B (miss), but adjusted EPS beat consensus by $6.68 vs $6.40 (+4.4%). Revenue miss is likely due to the microbiology divestiture and currency effects.
Risk Factors
- Revenue of $12.14B missed consensus of $12.86B, partly due to divestiture and FX
- No updated 2026 guidance provided, creating uncertainty
- Restructuring costs of $199M in Q3 (up from $135M YoY) could signal ongoing cost pressures
- Long-term debt increased to $39.1B from $35.9B at year-end 2025
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000097745-26-000173 |
| Document: tmo-20261021.htm | 0000097745-26-000173 |
| Document: 0000097745-26-000173-index-headers.html | 0000097745-26-000173 |
| Document: 0000097745-26-000173-index.html | 0000097745-26-000173 |
| Document: 0000097745-26-000173.txt | 0000097745-26-000173 |
| 8-K Data (Synthetic) | 0000097745-26-000173 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 6d ago | 8-K | $694.02 | awaiting T+60 | — | $693.02 (−0.14%) |
Oct 16, 2026 11d ago | Institutional Cluster | $690.00 | awaiting T+60 | — | $693.02 (+0.44%) |
Sep 1, 2026 8w ago | Insider Cluster | $608.54 | awaiting T+60 | — | $693.02 (+13.88%) |
Aug 26, 2026 8w ago | Insider Cluster | $630.70 | awaiting T+60 | — | $693.02 (+9.88%) |
Aug 24, 2026 9w ago | Insider Cluster | $628.15 | awaiting T+60 | — | $693.02 (+10.33%) |
Aug 18, 2026 10w ago | Court Ruling | $613.07 | awaiting T+60 | — | $693.02 (+13.04%) |
Aug 13, 2026 10w ago | Insider Cluster | $588.29 | awaiting T+60 | — | $693.02 (+17.80%) |
Aug 10, 2026 11w ago | Insider Cluster | $605.00 | awaiting T+60 | — | $693.02 (+14.55%) |
Aug 7, 2026 11w ago | Insider Cluster | $599.23 | awaiting T+60 | — | $693.02 (+15.65%) |
Jul 23, 2026 13w ago | 8-K | $572.32 $696.49 | ▲ +21.70% | ▲ +17.14% | $693.02 (+21.09%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers